Science
Mechanism of Action
This ingredient primarily operates through the well-documented mechanism of sh-Oligopeptide-1, a recombinant analog of human Epidermal Growth Factor (EGF). EGF acts as a crucial cellular signaling molecule, binding to the epidermal growth factor receptor (EGFR) on various skin cells, including keratinocytes and fibroblasts. This binding initiates a cascade of events leading to enhanced cell growth, proliferation, and differentiation, which are vital for skin repair and regeneration. It also supports the formation of new blood vessels and stimulates the release of other rejuvenating growth factors, contributing to scar-free wound healing. Furthermore, SR-(MELITTIN SH-OLIGOPEPTIDE-1) is understood to boost the synthesis of key extracellular matrix components like collagen, elastin, and hyaluronic acid. This action strengthens the skin barrier, reduces inflammation, provides sustained moisturization, and visibly diminishes the appearance of fine lines, wrinkles, and hyperpigmentation. The precise role or mechanistic contribution of the 'Melittin' component within this specific recombinant peptide, beyond its known potent pharmacological effects as a standalone bee venom peptide, is not elucidated in the provided skincare literature.
Research
Clinical Evidence
Low confidenceN/A
Transparency
Dusting Analysis
The Formula
Formulation
Stability
Maintaining the bioactivity of growth factors like sh-Oligopeptide-1 is notably challenging. In laboratory conditions, these peptides typically require storage at extremely low temperatures (-20°C) to ensure stability. In some product formulations at room temperature, only 5-10% of the growth factor may retain its activity. Advanced delivery systems, such as liposomes and nanocarriers, are actively being developed to improve the bioavailability and stability of such delicate peptides.
Safety
Safety Profile
Safety data specifically for SR-(MELITTIN SH-OLIGOPEPTIDE-1) as a combined ingredient is highly limited, with assessments primarily focused on sh-Oligopeptide-1 (EGF) alone. While sh-Oligopeptide-1 is often considered safe due to its natural occurrence in the human body, there are conflicting regulatory and scientific perspectives. Some sources authorize sh-EGF in cosmetics but acknowledge unknown long-term risks and unproven preclinical bioactivity in certain studies. Active EGF is also considered an unauthorized drug in some contexts, lacking sufficient medium- to long-term safety data for cosmetic applications. Significant concerns exist regarding its mitogenic activity (ability to increase cell numbers), prompting advice for individuals at risk of skin cancer or with psoriasis to avoid its use. Early tests have reportedly linked EGF use to psoriasis and skin irritation, potentially due to excessive skin cell production. Despite these concerns, EGFs themselves are not classified as mutagenic (cancer-causing). Neither the CIR nor the SCCS has specifically reviewed SR-(MELITTIN SH-OLIGOPEPTIDE-1) or sh-Oligopeptide-1. The FDA does not authorize topical recombinant human EGF as a medication outside of clinical trials. The safety profile of the 'Melittin' component within this recombinant structure for skincare is also not detailed in available information, although Melittin on its own is known to exhibit cytotoxic potential at certain concentrations.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While the sh-Oligopeptide-1 component offers promising regenerative benefits for addressing signs of aging and improving skin texture, the overall ingredient SR-(MELITTIN SH-OLIGOPEPTIDE-1) presents significant safety unknowns, particularly regarding its mitogenic potential, the unclarified role of Melittin, and severe formulation stability challenges, making its use in precision skincare highly questionable.
Related
Similar Ingredients
Finding similar ingredients…